Gabapentin Market Size Projected To Increase From $3.26 Billion To $4.45 Billion During The Forecast Period
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Gabapentin Market Revenue Outlook: What CAGR Is Expected Through 2030?
The gabapentin market has experienced significant expansion in recent years, with its value projected to rise from $3.01 billion in 2025 to $3.26 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.4%. This historical growth has been driven by several key factors, including the widespread adoption of epilepsy treatments, the increasing prevalence of neuropathic pain, the accessibility of generic drugs, established physician prescribing habits, and the growing burden of chronic diseases.
The gabapentin sector is projected to experience robust expansion in the coming years, with its valuation reaching an estimated $4.45 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.1%. This upward trajectory during the forecast period is primarily driven by factors such as an aging demographic, the increasing prevalence of diabetic neuropathy, greater market penetration of generic alternatives, a heightened focus on outpatient pain management approaches, and the growing utilization of telemedicine for prescription services. Key developments shaping this period include a rising application of the drug in treating neuropathic pain, a surging preference for generic versions, the broadening of chronic pain treatment initiatives, the proliferation of oral solid dosage forms, and a notable uptick in prescriptions targeting neurological conditions.
Download A Free Sample Report For Comprehensive Market Insights:
Gabapentin Market Growth Factors Supporting Long-Term Expansion
The rising frequency of epilepsy cases is anticipated to fuel the expansion of the gabapentin market in the coming period. Epilepsy is a neurological condition marked by recurring seizures resulting from abnormal electrical activity within the brain. This condition is becoming more common, largely due to the expanding older population, since aging elevates the likelihood of neurological disorders that trigger seizures. Gabapentin manages epilepsy by calming irregular nerve activity in the brain and reducing signals that lead to seizures. It functions by targeting calcium channels to aid in preventing seizure episodes. As an example, in February 2024, the World Health Organization (WHO), an intergovernmental organization based in Switzerland, reported that approximately 50 million people globally have epilepsy, with nearly 80% of those affected residing in low- and middle-income countries, and up to 70% could achieve seizure freedom with proper diagnosis and treatment. Each year, around 5 million individuals are newly diagnosed with epilepsy worldwide; this rate is about 49 per 100,000 in high-income nations, whereas in low- and middle-income countries it can reach as high as 139 per 100,000. Consequently, the growing prevalence of epilepsy is propelling the gabapentin market forward.
Gabapentin Market Segment Analysis Highlighting Growth Areas
The gabapentin market covered in this report is segmented –
1) By Type: Generic, Branded
2) By Dosage Form: Tablet, Capsule, Oral Solution
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By Application: Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Other Applications
Subsegments:
1) By Generic: Gabapentin Immediate Release (IR), Gabapentin Extended Release (ER), Gabapentin Capsules, Gabapentin Tablets, Gabapentin Oral Solution
2) By Branded: Neurontin, Gralise, Horizant, Other Branded Formulations
Gabapentin Market Industry Trends Shaping Future Revenue Growth
Key players in the gabapentin market are concentrating on the creation of sophisticated formulations, including bioequivalent tablets, aimed at improving therapeutic effectiveness and broadening treatment possibilities for neurological disorders. These bioequivalent tablets are generic medications that deliver an identical quantity of the active substance into the bloodstream at the same rate and efficiency as the original branded product, ensuring comparable safety and therapeutic outcomes. For example, in March 2024, Strides Pharma Science Limited, a pharmaceutical firm based in India, introduced Gabapentin Tablets USP in 600 mg and 800 mg strengths, which secured approval from the United States Food & Drug Administration (USFDA) to broaden its neurology offerings in the American market. This novel gabapentin formulation boasts increased bioavailability, accurate dosing, and patient-friendly administration, facilitating more uniform therapeutic results, enhanced symptom management, and increased ease for sustained treatment. The 600 mg Gabapentin Tablets USP present adaptable therapeutic applications, delivering effective control over various neurological conditions like neuropathic pain and partial seizures through dependable dosing and established clinical effectiveness.
Gabapentin Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC
Access The Complete Gabapentin Market Report:
Gabapentin Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the gabapentin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gabapentin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
